- Ideas
- Markets
- Cryptocurrencies
- Currencies
- Stocks
- Earnings Calendar
- Stock Screener
- Large-Cap
- Top Gainers
- Top Losers
- Most Active
- Most Volatile
- Overbought
- Oversold
- All Time High
- All Time Low
- Sector & Industry
Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc
- Indices
S&P 500, Nasdaq Composite, Dow 30, Nikkei 225, DAX Index, FTSE 100
- Futures
- Bonds
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
- CFDs
Gold, Brent Oil, Crude Oil, CFDs on Natural Gas, Palladium, Silver
- Scripts
- Oscillators
- Centered Oscillators
- Volatility
- Trend Analysis
- Volume
- Moving Average
- Exponential Moving Average (EMA)
- Weighted Moving Average (WMA)
- Simple Moving Average (SMA)
- Hull Moving Average (HMA)
- Kaufman's Adaptive Moving Average (KAMA)
- Smoothed Moving Average (SMMA)
- Variable Index Dynamic Average (VIDYA)
- Volume-weighted Moving Average (VWMA)
- Fractal Adaptive Moving Average (FRAMA)
- Double Exponential Moving Average (DEMA)
- Breadth Indicators
- Bill Williams Indicators
- Screener
- Shows
- Chart
- More
AVROBIO INC
NASDAQ
AVRO
AVRO
AVROBIO INC
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E
AVRO, 60
AVROBIO got a good pop today from very positive Phase 2 clinical trial results from its kidney drug. Unquestionably the news was good; the drug shows strong efficacy and no adverse events. However, this was only a Phase 2 trial so there's a long way still to go in the approval process. Meanwhile, the company is losing money and is rated as an overvalued and...
7
Valuation
Enterprise Value/EBITDA, TTM
—
Enterprise Value, FQ
—
Market Cap — Basic
—
Number of Employees
—
Number of Shareholders
—
Price/Earnings, TTM
—
Price/Revenue, TTM
—
Price/Book Ratio, FY
—
Price/Sales Ratio, FY
—
Balance Sheet
Current Ratio, FQ
—
Debt to Equity, FQ
—
Net Debt, FQ
—
Quick Ratio, FQ
—
Total Assets, FQ
—
Total Debt, FQ
—
Operating Metrics
Return on Assets, TTM
—
Return on Equity, TTM
—
Return on Invested Capital, TTM
—
Revenue per Employee, TTM
—
Price History
Average Volume (10 day)
—
Beta - 1 Year
—
Price - 52 Week High
—
Price - 52 Week Low
—
Dividends
Dividends Paid, FY
—
Dividends per Share, FY
—
Expected Annual Dividends
—
Dividends Yield
—
Margins
Net Margin, TTM
—
Gross Margin, TTM
—
Operating Margin, TTM
—
Pretax Margin, TTM
—
Income Statement
Basic EPS, Net Income
—
Earnings per Share, Basic, TTM
—
EBITDA, TTM
—
Gross Profit, FY
—
Last Annual EPS
—
Last Annual Revenue, FY
—
Net Income, FY
—
Total Revenue, FY
—
Free Cash Flow, TTM
—
Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 62
AVROBIO, Inc. is a clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.
News
Community & Tools
For Business
© 2019 TradingView
Stock Charts & Forex Charts
Stock Charts & Forex Charts
Made with
From the creators of MultiCharts
Select market data provided by ICE Data Services